The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.
UC Davis Comprehensive Cancer Center | Strategic Alliance Partners
Latest from UC Davis Comprehensive Cancer Center
Advertisement
Advertisement
Trending on CURE
1
Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study
2
Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial
3
Imfinzi Combo Improves Progression Free Survival in Ovarian Cancer
4
Trodelvy Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
5
